KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Co-Diagnostics (CODX) Tax Provisions (2020 - 2025)

Historic Tax Provisions for Co-Diagnostics (CODX) over the last 6 years, with Q3 2025 value amounting to -$1.2 million.

  • Co-Diagnostics' Tax Provisions fell 535752.85% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.2 million, marking a year-over-year decrease of 12950.17%. This contributed to the annual value of $57368.0 for FY2024, which is 10206.53% up from last year.
  • Co-Diagnostics' Tax Provisions amounted to -$1.2 million in Q3 2025, which was down 535752.85% from $12327.0 recorded in Q2 2025.
  • In the past 5 years, Co-Diagnostics' Tax Provisions registered a high of $3.8 million during Q4 2023, and its lowest value of -$3.1 million during Q4 2022.
  • Over the past 5 years, Co-Diagnostics' median Tax Provisions value was $12327.0 (recorded in 2025), while the average stood at $26613.7.
  • Per our database at Business Quant, Co-Diagnostics' Tax Provisions soared by 22214.43% in 2023 and then crashed by 535752.85% in 2025.
  • Co-Diagnostics' Tax Provisions (Quarter) stood at $2.7 million in 2021, then tumbled by 214.31% to -$3.1 million in 2022, then surged by 222.14% to $3.8 million in 2023, then crashed by 100.21% to -$8175.0 in 2024, then crashed by 14170.25% to -$1.2 million in 2025.
  • Its last three reported values are -$1.2 million in Q3 2025, $12327.0 for Q2 2025, and $12004.0 during Q1 2025.